EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review
<i>Background and Objectives</i>: Lung cancer remains the most common malignancy worldwide. As the global population ages, the prevalence of epidermal growth factor receptor (EGFR)-mutation-positive non-small cell lung cancer (NSCLC) is increasing. <i>Materials and Methods</i>...
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
MDPI AG
2022-11-01
|
| coleção: | Medicina |
| Assuntos: | |
| Acesso em linha: | https://www.mdpi.com/1648-9144/58/11/1645 |
| Resumo: | <i>Background and Objectives</i>: Lung cancer remains the most common malignancy worldwide. As the global population ages, the prevalence of epidermal growth factor receptor (EGFR)-mutation-positive non-small cell lung cancer (NSCLC) is increasing. <i>Materials and Methods</i>: We performed a meta-analysis and a systematic review of randomized, controlled trials to evaluate the efficacy of EGFR TKIs on progression-free survival (PFS) and overall survival (OS) in older adult patients with advanced EGFR-mutated NSCLC. A total of 1327 patients were included; among these, 662 patients were >65 years of age. <i>Results</i>: A pooled analysis indicated (1) an overall improvement in higher PFS for dacomitinib and osimetinib than that for other drugs (hazard ratio [HR] = 0.654, 95% CI: 0.474 to 0.903; <i>p</i> = 0.01) and (2) and no significant difference in the OS between the EGFR TKIs (HR = 0.989, 95% CI: 0.796 to 1.229; <i>p</i> = 921). <i>Conclusion</i>: Our study found that osimertinib achieved a higher PFS than all other EGFR TKIs did. Osimertinib is the preferred EGFR TKI for treatment of older adult patients with advanced EGFR-mutated NSCLC. |
|---|---|
| ISSN: | 1010-660X 1648-9144 |